<DOC>
	<DOCNO>NCT01713036</DOCNO>
	<brief_summary>This Phase 1 , open-label , single center trial evaluate mass balance , bioavailability metabolism pimasertib cancer subject locally advanced metastatic solid tumor .</brief_summary>
	<brief_title>Oral Bioavailability Mass Balance Trial With Pimasertib</brief_title>
	<detailed_description />
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male subject pathologically confirm solid tumor preferentially include , limited pancreatic , thyroid , colorectal , lung , renal cancer , melanoma locally advanced metastatic , either refractory respective standard therapy disease effective standard therapy available Subject measurable evaluable disease define Response Evaluation Criteria In Solid Tumors version 1.1 ( RECIST v.1.1 ) Age great equal 18 year less equal 65 year Body mass index great equal 19 less equal 30 kilogram per meter square ( kg/m^2 ) Subject Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) less equal 1 Male subject female partner childbearing potential must willing use adequate method contraception 4 week last dose trial medication . During time , female partner use contraceptive method failure rate le 1 percent Subject read understood inform consent form willing able give write informed consent trial related procedure perform Bone marrow impairment evidence hemoglobin le 10.0 gram per deciliter ( g/dL ) , neutrophil count le 1.5 * 10^9 per liter ( /L ) , and/or platelet le 100 * 10^9/L Renal impairment evidence serum creatinine great 1.5 * upper limit normal ( ULN ) calculate creatinine clearance le 60 milliliter per minute ( mL/min ) ( Cockcroft Gault formula ) Liver function liver cell integrity abnormality define total bilirubin great 1.5 * ULN , aspartate transaminase ( AST ) /alanine transaminase ( ALT ) great 2.5 * ULN , subject liver metastasis AST/ALT great 5 * ULN Primary brain tumor clinical evidence active brain metastasis . Subjects history previously treat brain tumor eligible provide 1 month follow treatment stable compute tomography ( CT ) scan without evidence cerebral edema , requirement anticonvulsant high dos corticosteroid History gastrointestinal disease , malabsorption syndrome difficulty swallowing , investigator 's opinion might impair absorption pimasertib Any gastric , small large bowel surgery may impact absorption pimasertib Known human immunodeficiency virus ( HIV ) positivity , active hepatitis Chemotherapy , radiotherapy , immunotherapy , molecular target cancer therapy within past 4 week within 5 halflives give drug , whatever longer , prior start trial medication concomitantly within trial . This restriction apply steroid bisphosphonates Major surgical procedure within last 8 week prior start trial medication History uveitis scleritis . Retinal pathology beyond normal agerelated process History glaucoma . Subjects exclude intraocular pressure 21 millimeter mercury ( mmHg ) Evidence retinal vein occlusion ( RVO ) fluorescein angiogram history RVO . Subjects also exclude examination ophthalmologist find optic disc risk central RVO Life expectancy le 12 week Clinically relevant nonmalignant disease investigator 's opinion would exclude subject trial , significant cardiovascular , pulmonary , endocrine , renal neurological disease psychiatric disorder Treatment strong inhibitor and/or inducer cytochrome P450 2C19 ( CYP2C19 ) cytochrome P450 3A4 ( CYP3A4 ) . Consumption CYP3A4 enzyme induce inhibit herbal drug , fruit juice beverage ( example , grapefruit , grapefruit juice , quinine [ tonic water ] , star fruit , St John 's Wort ) within 2 week prior start trial medication end Day 21 Participation drug trial within 30 day prior start trial medication . Participation trial involve administration [ 14C ] label compound ( ) within last 6 month prior start trial medication Known hypersensitivity excipients use Inability understand protocol requirement , instruction trialrelated restriction , nature , scope , possible consequence trial Legal incapacity limit legal capacity</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mass balance , bioavailability , cancer , 14C</keyword>
</DOC>